Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Head & Neck 5Gastrointestinal 5CNS 5Thoracic 4Other hematologic neoplasm 4Lymphoid 4Dermatologic 2Breast 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1NET 1Gynecologic 1Endocrine 1

Conditions

Smoldering Multiple Myeloma 1

Interventions

Dexamethasone 124daratumumab 73Lenalidomide 72Bortezomib 61pomalidomide 45Cyclophosphamide 41carfilzomib 40Calcium Dobesilate 36Specimen Handling 34Biopsy 30Magnetic Resonance Spectroscopy 27belantamab mafodotin 24isatuximab 20fludarabine 20dexamethasone acetate 18dexamethasone 21-phosphate 18auricularum 18Melphalan 18talquetamab 16iberdomide 16fludarabine phosphate 12selinexor 11elotuzumab 10X-Rays 10tocilizumab 9Nivolumab 8Sirolimus 7Crizotinib 7trametinib 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Watchful Waiting × Plasma cell × 90 days × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡